Seminars in Hematology
Volume 44 , Pages S24-S34 , October 2007

Other Immune Thrombocytopenias

  • Howard Liebman

      Affiliations

    • Corresponding Author InformationAddress correspondence to Professor Howard A. Liebman, MD, Norris Cancer Hospital, RM 3466, 1441 Eastlake Ave, Los Angeles, CA 90033.

References 

  1. Bussel J, Cines D. Immune thrombocytopenic purpura, neonatal alloimmune thrombocytopenia, and post-transfusion purpura. In:  Hoffman R editors. Hematology: Basic Principles and Practice. (ed 4). Philadelphia: Elsevier Churchill Livingstone; 2005;
  2. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346:995–1008
  3. Gasbarrini A, Franceschi F, Tartaglione R, Landolfi R, Pola P, Gasbarrini G. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet. 1998;352:878
  4. Hedge UM, Zuiable A, Ball S, Roter BL. The relative incidence of idiopathic and secondary autoimmune thrombocytopenia: a clinical and serological evaluation in 508 patients. Clin Lab Haematol. 1985;7:7–16
  5. Helmerhorst FM, van Leeuwen EF, Pegels JG, van der Plas-van Dalen C, Eengelfriet CP, von dem Borne AE. Primary and secondary autoimmune thrombocytopenia (A serological and clinical analysis). Scand J Haematol. 1982;28:319–328
  6. Berkman AW, Kickler T, Braine H. Platelet-associated IgG in patients with lymphoma. Blood. 1984;63:944–948
  7. Kuznetsov AI, Ivanov AL, Idelson LI, Mazurov AV. Mechanisms of thrombocytopenia in patients with lymphoproliferative diseases. Eur J Haematol. 1992;49:113–118
  8. Rubinstein DB, Longo DL. Peripheral destruction of platelets in chronic lymphocytic leukemia: Recognition, prognosis and therapeutic implications. Am J Med. 1981;71:729–732
  9. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219–234
  10. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198–206
  11. Lim SH, Ifthikharuddin JJ. Autoimmune thrombocytopenic purpura complicating lymphoproliferative disorders. Leuk Lymphoma. 1994;15:61–64
  12. Duhrsen U, Augener W, Zwingers T, Brittinger G. Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: Analysis of 637 cases and comparison with myeloproliferative diseases. Br J Haematol. 1987;67:235–239
  13. Hamblin TJ, Oscier DG, Young BJ. Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol. 1986;39:713–716
  14. Xiros N, Binder T, Anger B, Bohlke J, Heimpel H. Idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia in Hodgkin’s disease. Eur J Haematol. 1988;40:437–441
  15. Kirshner JJ, Zamkoff KW, Gottlieb AJ. Idiopathic thrombocytopenic purpura and Hodgkin’s disease: Report of two cases and a review of the literature. Am J Med Sci. 1980;280:21–28
  16. Fink K, Al-Mondhiry H. Idiopathic thrombocytopenic purpura in lymphoma. Cancer. 1976;37:1999–2004
  17. Pedro-Botet J, Estruch R, Montserrat E, Urbano-Marquez A, Rozman C. Thrombocytopenic purpura as first manifestation of an inapparent Hodgkin’s disease. Scand J Haematol. 1986;36:408–410
  18. Cohen JR. Idiopathic thrombocytopenic purpura in Hodgkin’s disease: A rare occurrence of no prognostic significance. Cancer. 1978;41:743–746
  19. Jones SE. Autoimmune disorders and malignant lymphoma. Cancer. 1973;31:1092–1098
  20. Aghai E, Quitt M, Lurie M, et al. Primary hepatic lymphoma presenting as symptomatic immune thrombocytopenic purpura. Cancer. 1987;60:2308–2311
  21. Kim HD, Boggs DR. A syndrome resembling idiopathic thrombocytopenic purpura in 10 patients with diverse forms of cancer. Am J Med. 1979;67:371–377
  22. Lehman HA, Lehman LO, Rustagi PK, Rustgi RN, Plunkett RW, Farolino DL, et al. Complement-mediated autoimmune thrombocytopenia (Monoclonal IgM antiplatelet antibody associated with lymphoreticular malignant disease). N Engl J Med. 1987;316:194–198
  23. Nossent JC, Swaak AJ. Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus. Q J Med. 1991;80:605–612
  24. Pistiner M, Wallace DJ, Nessim S, Metzger AL, Klinenberg JR. Lupus erythematosus in the 1980s: A survey of 570 patients. Semin Arthritis Rheum. 1991;21:55–64
  25. George JN, Vesely SK, James JA. Overlapping features of thrombotic thrombocytopenic purpura and systemic lupus erythematosus. South Med J. 2007;100:512–514
  26. Hunt L, Li X, James J, Terrell DR, Lammle B, Kremer-Hovinga J, et al. Thrombotic thrombocytopenic purpura (TTP) and systemic lupus erythematosus (SLE): Distinct but potentially overlapping syndromes. ASH Annual Meeting Abstracts. 2004;104:858;(abstr)
  27. Cervera R, Asherson RA. Clinical and epidemiological aspects in the antiphospholipid syndrome. Immunobiology. 2003;207:5–11
  28. Rubenstein E, Arkfeld DG, Metyas S, Shinada S, Ehresmann S, Liebman HA. Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol. 2006;33:355–357
  29. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88:3–40
  30. Kurata Y, Nishioeda Y, Tsubakio T, Kitani T. Thrombocytopenia in Graves’ disease: Effect of T3 on platelet kinetics. Acta Haematol. 1980;63:185–190
  31. Marshall J, Weisberger A, Levy R, Breckenridge R. Coexistent idiopathic thrombocytopenic purpura and hyperthyroidism. Ann Intern Med. 1967;67:411–414
  32. Herman J, Resnitzky P, Fink A. Association between thyrotoxicosis and thrombocytopenia (A case report and review of the literature). Isr J Med Sci. 1978;14:469–475
  33. DeGroot LJ, Larsen PR, Hennemann G. The Thyroid and Its Diseases. (ed 6). New York, NY: Churchill Livingstone; 1996;
  34. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature. Blood. 2003;101:1827–1832
  35. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306
  36. Arfors L, Winiarski J, Lefvert AK. Prevalence of antibodies to cardiolipin in chronic ITP and reactivity with platelet membranes. Eur J Haematol. 1996;56:230–234
  37. Bidot CJ, Jy W, Horstman LL, Ahn ER, Jimenez JJ, Yaniz M, et al. Antiphospholipid antibodies in immune thrombocytopenic purpura tend to emerge in exacerbation and decline in remission. Br J Haematol. 2005;128:366–372
  38. Bidot CJ, Jy W, Horstman LL, Ahn ER, Yaniz M, Ahn YS. Antiphospholipid antibodies (APLA) in immune thrombocytopenic purpura (ITP) and antiphospholipid syndrome (APS). Am J Hematol. 2006;81:391–396
  39. Diz-Kucukkaya R, Hacihanefioglu A, Yenerel M, Turgut M, Keskin H, Nalcaci M, et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: A prospective cohort study. Blood. 2001;98:1760–1764
  40. Lipp E, von Felten A, Sax H, Muller D, Berchtold P. Antibodies against platelet glycoproteins and antiphospholipid antibodies in autoimmune thrombocytopenia. Eur J Haematol. 1998;60:283–288
  41. Stasi R, Stipa E, Masi M, Oliva F, Sciarra A, Perrotti A, et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood. 1994;84:4203–4208
  42. Dash S, Marwaha RK, Mohanty S. Lupus anticoagulant in immune thrombocytopenic purpura. Indian J Pediatr. 2004;71:505–507
  43. Pullarkat V, Ngo M, Iqbal S, Espina B, Liebman HA. Detection of lupus anticoagulant identifies patients with autoimmune haemolytic anaemia at increased risk for venous thromboembolism. Br J Haematol. 2002;118:1166–1169
  44. de Groot PG, Lutters B, Derksen RH, Lisman T, Meijers JC, Rosendaal FR. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost. 2005;3:1993–1997
  45. Morris L, Distenfeld A, Amorosi E, Karpatkin S. Autoimmune thrombocytopenic purpura in homosexual men. Ann Intern Med. 1982;96:714–717
  46. Kaslow RA, Phair JP, Friedman HB, Lyter D, Solomon RE, Dudley J, et al. Infection with the human immunodeficiency virus: Clinical manifestations and their relationship to immune deficiency (A report from the Multicenter AIDS Cohort Study). Ann Intern Med. 1987;107:474–480
  47. Mientjes GH, van Ameijden EJ, Mulder JW, van den Hoek JA, Coutinho RA, von dem Borne AE. Prevalence of thrombocytopenia in HIV-infected and non-HIV infected drug users and homosexual men. Br J Haematol. 1992;82:615–619
  48. Murphy MF, Metcalfe P, Waters AH, Carne CA, Weller IV, Linch DC, et al. Incidence and mechanism of neutropenia and thrombocytopenia in patients with human immunodeficiency virus infection. Br J Haematol. 1987;66:337–340
  49. Peltier JY, Lambin P, Doinel C, Courouce AM, Rouger P, Lefrere JJ. Frequency and prognostic importance of thrombocytopenia in symptom-free HIV-infected individuals: A 5-year prospective study. Aids. 1991;5:381–384
  50. Rossi G, Gorla R, Stellini R, Franceschini F, Bettinzioli M, Cadeo G, et al. Prevalence, clinical, and laboratory features of thrombocytopenia among HIV-infected individuals. AIDS Res Hum Retroviruses. 1990;6:261–269
  51. Sloand EM, Klein HG, Banks SM, Vareldzis B, Merritt S, Pierce P. Epidemiology of thrombocytopenia in HIV infection. Eur J Haematol. 1992;48:168–172
  52. Sullivan PS, Hanson DL, Chu SY, Jones JL, Ciesielski CA. Surveillance for thrombocytopenia in persons infected with HIV: Results from the multistate Adult and Adolescent Spectrum of Disease Project. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:374–379
  53. Berhane K, Karim R, Cohen MH, Masri-Lavine L, Young M, Anastos K, et al. Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women’s Interagency HIV Study. J Acquir Immune Defic Syndr. 2004;37:1245–1252
  54. Levine AM, Karim R, Mack W, Gravink DJ, Anastos K, Young M, et al. Neutropenia in human immunodeficiency virus infection: data from the women’s interagency HIV study. Arch Intern Med. 2006;166:405–410
  55. Finazzi G, Mannucci PM, Lazzarin A, Gringeri A, Arici C, Ciaci D, et al. Low incidence of bleeding from HIV-related thrombocytopenia in drug addicts and hemophiliacs: Implications for therapeutic strategies. Eur J Haematol. 1990;45:82–85
  56. Ragni MV, Bontempo FA, Myers DJ, Kiss JE, Oral A. Hemorrhagic sequelae of immune thrombocytopenic purpura in human immunodeficiency virus-infected hemophiliacs. Blood. 1990;75:1267–1272
  57. Logan RP, Walker MM. ABC of the upper gastrointestinal tract: Epidemiology and diagnosis of Helicobacter pylori infection. BMJ. 2001;323:920–922
  58. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347:1175–1186
  59. Ando K, Shimamoto T, Tauchi T, Ito Y, Kuriyama Y, Gotoh A, et al. Can eradication therapy for Helicobacter pylori really improve the thrombocytopenia in idiopathic thrombocytopenic purpura? (Our experience and a literature review). Int J Hematol. 2003;77:239–244
  60. Veneri D, De Matteis G, Solero P, Federici F, Zanuso C, Guizzardi E, et al. Analysis of B- and T-cell clonality and HLA class II alleles in patients with idiopathic thrombocytopenic purpura: Correlation with Helicobacter pylori infection and response to eradication treatment. Platelets. 2005;16:307–311
  61. Ando T, Tsuzuki T, Mizuno T, Minami M, Ina K, Kusugami K, et al. Characteristics of Helicobacter pylori-induced gastritis and the effect of H. pylori eradication in patients with chronic idiopathic thrombocytopenic purpura. Helicobacter. 2004;9:443–452
  62. Emilia G, Longo G, Luppi M, Gandini G, Morselli M, Ferrara L, et al. Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura. Blood. 2001;97:812–814
  63. Fujimura K, Kuwana M, Kurata Y, Imamura M, Harada H, Sakamaki H, et al. Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? (Analysis of 207 eradicated chronic ITP cases in Japan). Int J Hematol. 2005;81:162–168
  64. Hashino S, Mori A, Suzuki S, Izumiyama K, Kahata K, Yonezumi M, et al. Platelet recovery in patients with idiopathic thrombocytopenic purpura after eradication of Helicobacter pylori. Int J Hematol. 2003;77:188–191
  65. Hino M, Yamane T, Park K, Takubo T, Ohta K, Kitagawa S, et al. Platelet recovery after eradication of Helicobacter pylori in patients with idiopathic thrombocytopenic purpura. Ann Hematol. 2003;82:30–32
  66. Inaba T, Mizuno M, Take S, Suwaki K, Honda T, Kawai K, et al. Eradication of Helicobacter pylori increases platelet count in patients with idiopathic thrombocytopenic purpura in Japan. Eur J Clin Invest. 2005;35:214–219
  67. Jarque I, Andreu R, Llopis I, De la Rubia J, Gomis F, Senent L, et al. Absence of platelet response after eradication of Helicobacter pylori infection in patients with chronic idiopathic thrombocytopenic purpura. Br J Haematol. 2001;115:1002–1003
  68. Kohda K, Kuga T, Kogawa K, Kanisawa Y, Koike K, Kuroiwa G, et al. Effect of Helicobacter pylori eradication on platelet recovery in Japanese patients with chronic idiopathic thrombocytopenic purpura and secondary autoimmune thrombocytopenic purpura. Br J Haematol. 2002;118:584–588
  69. Michel M, Cooper N, Jean C, Frissora C, Bussel JB. Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura?. Blood. 2004;103:890–896
  70. Nomura S, Inami N, Kanazawa S. The effects of Helicobacter pylori eradication on chemokine production in patients with immune thrombocytopenic purpura. Eur J Haematol. 2004;72:304–305
  71. Sato R, Murakami K, Watanabe K, Okimoto T, Miyajima H, Ogata M, et al. Effect of Helicobacter pylori eradication on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura. Arch Intern Med. 2004;164:1904–1907
  72. Stasi R, Rossi Z, Stipa E, Amadori S, Newland AC, Provan D. Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura. Am J Med. 2005;118:414–419
  73. Suvajdzic N, Stankovic B, Artiko V, Cvejic T, Bulat V, Bakrac M, et al. Helicobacter pylori eradication can induce platelet recovery in chronic idiopathic thrombocytopenic purpura. Platelets. 2006;17:227–230
  74. Suzuki T, Matsushima M, Masui A, Watanabe K, Takagi A, Ogawa Y, et al. Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura—A randomized controlled trial. Am J Gastroenterol. 2005;100:1265–1270
  75. Takahashi T, Yujiri T, Shinohara K, Inoue Y, Sato Y, Fujii Y, et al. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. Br J Haematol. 2004;124:91–96
  76. Veneri D, Franchini M, Gottardi M, D’Adda M, Ambrosetti A, Krampera M, et al. Efficacy of Helicobacter pylori eradication in raising platelet count in adult patients with idiopathic thrombocytopenic purpura. Haematologica. 2002;87:1177–1179
  77. Rajantie J, Klemola T. Helicobacter pylori and idiopathic thrombocytopenic purpura in children. Blood. 2003;101:1660
  78. Yetgin S, Demir H, Arslan D, Unal S, Kocak N. Autoimmune thrombocytopenic purpura and Helicobacter pylori infection effectivity during childhood. Am J Hematol. 2005;78:318
  79. Garcia-Suarez J, Burgaleta C, Hernanz N, Albarran F, Tobaruela P, Alvarez-Mon M. HCV-associated thrombocytopenia: Clinical characteristics and platelet response after recombinant alpha2b-interferon therapy. Br J Haematol. 2000;110:98–103
  80. Pawlotsky JM, Bouvier M, Fromont P, Deforges L, Duval J, Dhumeaux D, et al. Hepatitis C virus infection and autoimmune thrombocytopenic purpura. J Hepatol. 1995;23:635–639
  81. Pivetti S, Novarino A, Merico F, Tiziana Bertero M, Brunetto MR, Bonino F, et al. High prevalence of autoimmune phenomena in hepatitis C virus antibody positive patients with lymphoproliferative and connective tissue disorders. Br J Haematol. 1996;95:204–211
  82. Rajan SK, Espina BM, Liebman HA. Hepatitis C virus-related thrombocytopenia: Clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura. Br J Haematol. 2005;129:818–824
  83. Sakuraya M, Murakami H, Uchiumi H, Hatsumi N, Akiba T, Yokohama A, et al. Steroid-refractory chronic idiopathic thrombocytopenic purpura associated with hepatitis C virus infection. Eur J Haematol. 2002;68:49–53
  84. Zhang L, Li H, Zhao H, Ji L, Yang R. Hepatitis C virus-related adult chronic idiopathic thrombocytopenic purpura: Experience from a single Chinese center. Eur J Haematol. 2003;70:196–197
  85. Pockros PJ, Duchini A, McMillan R, Nyberg LM, McHutchison J, Viernes E. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 2002;97:2040–2045
  86. Chong BH, Keng TB. Advances in the diagnosis of idiopathic thrombocytopenic purpura. Semin Hematol. 2000;37:249–260
  87. McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol. 2000;37:239–248
  88. McMillan R. The pathogenesis of chronic immune (idiopathic) thrombocytopenic purpura. Semin Hematol. 2000;37(suppl 1):5–9
  89. He R, Reid DM, Jones CE, Shulman NR. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood. 1994;83:1024–1032
  90. Shi W, Chong BH, Chesterman CN. Beta 2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants. Blood. 1993;81:1255–1262
  91. Nojima J, Suehisa E, Kuratsune H, Machii T, Koike T, Kitani T, et al. Platelet activation induced by combined effects of anticardiolipin and lupus anticoagulant IgG antibodies in patients with systemic lupus erythematosus—Possible association with thrombotic and thrombocytopenic complications. Thromb Haemost. 1999;81:436–441
  92. Walsh CM, Nardi MA, Karpatkin S. On the mechanism of thrombocytopenic purpura in sexually active homosexual men. N Engl J Med. 1984;311:635–639
  93. Karpatkin S, Nardi M, Lennette ET, Byrne B, Poiesz B. Anti-human immunodeficiency virus type 1 antibody complexes on platelets of seropositive thrombocytopenic homosexuals and narcotic addicts. Proc Natl Acad Sci U S A. 1988;85:9763–9767
  94. Karpatkin S, Nardi M. Autoimmune anti-HIV-1gp120 antibody with antiidiotype-like activity in sera and immune complexes of HIV-1-related immunologic thrombocytopenia. J Clin Invest. 1992;89:356–364
  95. Karpatkin S, Nardi MA, Hymes KB. Sequestration of anti-platelet GPIIIa antibody in rheumatoid factor immune complexes of human immunodeficiency virus 1 thrombocytopenic patients. Proc Natl Acad Sci U S A. 1995;92:2263–2267
  96. Samuel H, Nardi M, Karpatkin M, Hart D, Belmont M, Karpatkin S. Differentiation of autoimmune thrombocytopenia from thrombocytopenia associated with immune complex disease: Systemic lupus erythematosus, hepatitis-cirrhosis, and HIV-1 infection by platelet and serum immunological measurements. Br J Haematol. 1999;105:1086–1091
  97. Bettaieb A, Oksenhendler E, Fromont P, Duedari N, Bierling P. Immunochemical analysis of platelet autoantibodies in HIV-related thrombocytopenic purpura: A study of 68 patients. Br J Haematol. 1989;73:241–247
  98. Nardi MA, Liu LX, Karpatkin S. GPIIIa-(49-66) is a major pathophysiologically relevant antigenic determinant for anti-platelet GPIIIa of HIV-1-related immunologic thrombocytopenia. Proc Natl Acad Sci U S A. 1997;94:7589–7594
  99. Bettaieb A, Fromont P, Louache F, Oksenhendler E, Vainchenker W, Duedari N, et al. Presence of cross-reactive antibody between human immunodeficiency virus (HIV) and platelet glycoproteins in HIV-related immune thrombocytopenic purpura. Blood. 1992;80:162–169
  100. Hohmann AW, Booth K, Peters V, Gordon DL, Comacchio RM. Common epitope on HIV p24 and human platelets. Lancet. 1993;342:1274–1275
  101. Nardi M, Tomlinson S, Greco MA, Karpatkin S. Complement-independent, peroxide-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia. Cell. 2001;106:551–561
  102. Ballem PJ, Belzberg A, Devine DV, Lyster D, Spruston B, Chambers H, et al. Kinetic studies of the mechanism of thrombocytopenia in patients with human immunodeficiency virus infection. N Engl J Med. 1992;327:1779–1784
  103. Zucker-Franklin D, Termin CS, Cooper MC. Structural changes in the megakaryocytes of patients infected with the human immune deficiency virus (HIV-1). Am J Pathol. 1989;134:1295–1303
  104. Sato T, Sekine H, Kakuda H, Miura N, Sunohara M, Fuse A. HIV infection of megakaryocytic cell lines. Leuk Lymphoma. 2000;36:397–404
  105. Sundell IB, Koka PS. Thrombocytopenia in HIV infection: impairment of platelet formation and loss correlates with increased c-Mpl and ligand thrombopoietin expression. Curr HIV Res. 2006;4:107–116
  106. Li Z, Nardi MA, Karpatkin S. Role of molecular mimicry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia. Blood. 2005;106:572–576
  107. Franceschi F, Christodoulides N, Kroll MH, Genta RM. Helicobacter pylori and idiopathic thrombocytopenic purpura. Ann Intern Med. 2004;140:766–767
  108. Yabu K, Kiyosawa K, Ako S, Usuda S, Yoshizawa K, Tanaka E, et al. Type C chronic hepatitis associated with thrombocytopenia in two patients. J Gastroenterol Hepatol. 1994;9:99–104
  109. Adinolfi LE, Giordano MG, Andreana A, Tripodi MF, Utili R, Cesaro G, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol. 2001;113:590–595
  110. Hamaia S, Li C, Allain JP. The dynamics of hepatitis C virus binding to platelets and 2 mononuclear cell lines. Blood. 2001;98:2293–2300
  111. Bordin G, Ballare M, Zigrossi P, Bertoncelli MC, Paccagnino L, Baroli A, et al. A laboratory and thrombokinetic study of HCV-associated thrombocytopenia: A direct role of HCV in bone marrow exhaustion?. Clin Exp Rheumatol. 1995;13(suppl 13):S39–S43
  112. Pockros PJ, Duchini A, McMillan R, Nyberg LM, McHutchison J, Viernes E. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 2002;97:2040–2045
  113. Nagamine T, Ohtuka T, Takehara K, Arai T, Takagi H, Mori M. Thrombocytopenia associated with hepatitis C viral infection. J Hepatol. 1996;24:135–140
  114. Carey RW, McGinnis A, Jacobson BM, Carvalho A. Idiopathic thrombocytopenic purpura complicating chronic lymphocytic leukemia. Arch Intern Med. 1976;136:62–66
  115. Kaden BR, Rosse WF, Hauch TW. Immune thrombocytopenia in lymphoproliferative diseases. Blood. 1979;53:545–551
  116. Hegde UP, Wilson WH, White T, Cheson BD. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood. 2002;100:2260–2262
  117. Gupta N, Kavuru S, Patel D, Janson D, Driscoll N, Ahmed S, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia. 2002;16:2092–2095
  118. Arnal C, Piette JC, Leone J, Taillan B, Hachulla E, Roudot-Thoraval F, et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol. 2002;29:75–83
  119. Adrouny A, Sandler RM, Carmel R. Variable presentation of thrombocytopenia in Graves’ disease. Arch Intern Med. 1982;142:1460–1464
  120. Hofbauer LC, Spitzweg C, Schmauss S, Heufelder AE. Graves disease associated with autoimmune thrombocytopenic purpura. Arch Intern Med. 1997;157:1033–1036
  121. Sugimoto K, Sasaki M, Isobe Y, Tamayose K, Hieda M, Oshimi K. Improvement of idiopathic thrombocytopenic purpura by antithyroid therapy. Eur J Haematol. 2005;74:73–74
  122. Bowles KM, Turner GE, Wimperis JZ. Resolution of chronic severe refractory thrombocytopenia after treatment of hypothyroidism. J Clin Pathol. 2004;57:995–996
  123. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98:952–957
  124. Erdozain JG, Ruiz-Irastorza G, Egurbide MV, Aguirre C. Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome. Haematologica. 2004;89:ECR34
  125. Walsh C, Krigel R, Lennette E, Karpatkin S. Thrombocytopenia in homosexual patients (Prognosis, response to therapy, and prevalence of antibody to the retrovirus associated with the acquired immunodeficiency syndrome). Ann Intern Med. 1985;103:542–545
  126. Scaradavou A, Woo B, Woloski BM, Cunningham-Rundles S, Ettinger LJ, Aledort LM, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood. 1997;89:2689–2700
  127. Oksenhendler E, Bierling P, Farcet JP, Rabian C, Seligmann M, Clauvel JP. Response to therapy in 37 patients with HIV-related thrombocytopenic purpura. Br J Haematol. 1987;66:491–495
  128. Landonio G, Galli M, Nosari A, Lazzarin A, Cipriani D, Crocchiolo P, et al. HIV-related severe thrombocytopenia in intravenous drug users: prevalence, response to therapy in a medium-term follow-up, and pathogenetic evaluation. Aids. 1990;4:29–34
  129. Servais J, Nkoghe D, Schmit JC, Arendt V, Robert I, Staub T, et al. HIV-associated hematologic disorders are correlated with plasma viral load and improve under highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28:221–225
  130. Landonio G, Cinque P, Nosari A, Gafa S, Rizzo F, Coen M, et al. Comparison of two dose regimens of zidovudine in an open, randomized, multicentre study for severe HIV-related thrombocytopenia. Aids. 1993;7:209–212
  131. Burbano X, Miguez MJ, Lecusay R, Rodriguez A, Ruiz P, Morales G, et al. Thrombocytopenia in HIV-infected drug users in the HAART era. Platelets. 2001;12:456–461
  132. Miguez MJ, Burbano X, Archer H, Shor-Posner G. Limited impact of highly active antiretroviral therapy in thrombocytopenia. J Acquir Immune Defic Syndr. 2002;30:260–261
  133. Suzuki T, Matsushima M, Masui A, Watanabe K-i, Takagi A, Ogawa Y, et al. Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura: A randomized controlled trial. Am J Gastroenterol. 2005;100:1265–1270
  134. Veneri D, Krampera M, Franchini M. High prevalence of sustained remission of idiopathic thrombocytopenic purpura after Helicobacter pylori eradication: A long-term follow-up study. Platelets. 2005;16:117–119
  135. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 2001;358:958–965
  136. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36(suppl 1):S237–S244
  137. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  138. Hernandez F, Blanquer A, Linares M, Lopez A, Tarin F, Cervero A. Autoimmune thrombocytopenia associated with hepatitis C virus infection. Acta Haematol. 1998;99:217–220
  139. Ramos-Casals M, Garcia-Carrasco ML, Lopez-Medrano F, Trejo O, Forns X, Lopez-Guillermo A, et al. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: Clinical description of 35 cases. Medicine (Baltimore). 2003;82:87
  140. Garcia-Suarez J, Burgaleta C, Hernanz N, Albarran F, Tobaruela P, Alvarez-Mon M. HCV-associated thrombocytopenia: clinical characteristics and platelet response after recombinant α2b-interferon therapy. Br J Haematol. 2000;110:98–103
  141. Iga D, Tomimatsu M, Endo H, Ohkawa S-I, Yamada O. Improvement of thrombocytopenia with disappearance of HCV RNA in patients treated by interferon-αB1; therapy: Possible etiology of HCV-associated immune thrombocytopenia. Eur J Haematol. 2005;75:417–423
  142. Rajan S, Liebman HA. Treatment of hepatitis C related thrombocytopenia with interferon alpha. Am J Hematol. 2001;68:202–209
  143. Schwartz J, Bussel JB. Anti-CD40L: Biology and therapy in ITP. Blood. 2004;103:1178–1179
  144. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, Broxmeyer HE, Kudelka AP, Freedman RS, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000;132:364–368
  145. Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Grigg AP, et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood. 1997;89:3118–3128
  146. Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Hussein S, et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet. 1996;348:1279–1281
  147. Kuter D, Bussel J, George J, Aledort L, Lichtin A, Lyons R, et al. Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 48-week update. ASH Annual Meeting Abstracts. 2006;108:476;(abstr)
  148. McHutchison JG, Afdhal N, Shiffman ML, Gordon S, Mills P, Sigal S, et al: Efficacy and safety of eltrombopag, an oral platelet growth factor, in subjects with HCV associated thrombocytopenia: Preliminary results from a phase II multicenter, randomised, placebo controlled, double-blind, dose-ranging study. Proceeding of the Annual Meeting of the American Association for the Study of Liver Diseases, 2006 (abstr LB3)
  149. Bussel JB, Cheng G, Saleh M, Kovaleva L, Stone N, Mayer B, et al. Analysis of bleeding in patients with immune thrombocytopenic purpura (ITP): A randomized, double-blind, placebo-controlled trial of eltrombopag, an oral platelet growth factor. ASH Annual Meeting Abstracts. 2006;108:475;(abstr)
  150. Bussel JB, Provan A, Shamsi T, Cheng G, Kovaleva L, Stone N, et al: Eltrombopag raises platelet count and reduces bleeding compared with placebo during short-term treatment in chronic idiopathic thrombocytopenic purpura: a phase III study. 12th Congress of the European Hematology Association, Vienna, Austria, June 7-10, 2007 (abstr 0390)
  151. Huhn RD, Fogarty PF, Nakamura R, Read EJ, Leitman SF, Rick ME, et al. High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood. 2003;101:71–77
  152. Pawlotsky J-M, Bouvier M, Fromont P, Deforges L, Duval J, Dhumeaux D, et al. Hepatitis C virus infection and autoimmune thrombocytopenic purpura. J Hepatol. 1995;23:635–639

 STATEMENT OF CONFLICT OF INTEREST: Dr Liebman has received grant/research support from GlaxoSmithKline, Amgen, Bristol-Myers Squibb, and Pharmion; he has received consulting fees from GlaxoSmithKline, Amgen, and Bristol-Myers Squibb.

PII: S0037-1963(07)00161-8

doi: 10.1053/j.seminhematol.2007.11.004

Seminars in Hematology
Volume 44 , Pages S24-S34 , October 2007

Article Tools

* Image Usage & Resolution